Shares of pharmaceutical companies Amylin, Alkermes, and Eli Lilly — partners in a new diabetes drug Bydureon — have tanked in morning trading as the U.S. Food and Drug Administration declined on Tuesday to approve the drug without additional clinical studies.
Continue reading Lilly, Amylin, Alkermes Shares Get Crushed After FDA Rejects Diabetes Drug
Lilly, Amylin, Alkermes Shares Get Crushed After FDA Rejects Diabetes Drug originally appeared on DailyFinance on Wed, 20 Oct 2010 10:40:00.
Filed Under: Company News, Health Care, GlaxoSmithKline, Eli Lilly, Stocks in the News